BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25443518)

  • 1. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
    Dilworth TJ; Ibrahim OM; Mercier RC
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
    Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
    Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
    Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
    BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial.
    Newberry L; O'Hare B; Kennedy N; Selman A; Omar S; Dawson P; Stevenson K; Nishihara Y; Lissauer S; Molyneux E
    Paediatr Int Child Health; 2017 May; 37(2):121-128. PubMed ID: 28145162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
    Tritle BJ; Hejazi AA; Timbrook TT
    Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimethoprim/sulfamethoxazole and metabolic acidosis in HIV-infected patients.
    Porras MC; Lecumberri JN; Castrillón JL
    Ann Pharmacother; 1998 Feb; 32(2):185-9. PubMed ID: 9496402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
    BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
    Para MF; Finkelstein D; Becker S; Dohn M; Walawander A; Black JR
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):337-43. PubMed ID: 11015150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
    Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
    Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.